

Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

### **A32 Monoclonal Antibody Fusion Protein for Use as HIV Inhibitors and Vaccines**

Dimiter S. Dimitrov and Mei-yun Zhang (NCI).  
U.S. Provisional Application No. 60/618,820 filed 14 Oct 2004 (HHS Reference No. E-302-2004/0-US-01).  
*Licensing Contact:* Sally Hu; 301/435-5606; [hus@mail.nih.gov](mailto:hus@mail.nih.gov).

The invention provides composition claims of a fusion protein, which comprises an antigen binding portion of a human antibody called A32 and one of the following: (a) An antigen-binding portion of a second antibody that binds to an epitope of an envelope protein (*i.e.*, gp120) of a human immunodeficiency virus (HIV) that is exposed upon the HIV binding to a CD4 receptor, (b) an immunogenic portion of an envelope protein of a HIV such as gp120, or (c) a soluble CD4 (sCD4) polypeptide capable of binding to HIV. The invention also provides the method claims to use the above fusion proteins as inhibitors of HIV infection and those containing gp120 such as A32-gp120 as vaccine immunogens for the treatment and prevention of HIV. Further development of the fusion proteins may yield novel therapies and methods in the prevention of mother-to-child transmission of HIV, treatment of accidental exposure to HIV, and chronic infection in patients with resistance to current therapies.

In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.

### **Plasmid and Viral Vectors Expressing a Microtubule-Directed Fluorescent Fusion Protein for Cellular Imaging**

Dr. Michael J. Iadarola *et al.* (NIDCR).  
HHS Reference No. E-153-1999/0—  
Research Tool.  
*Licensing Contact:* Marlene Shinn-Astor; 301/435-4426; [shinnm@mail.nih.gov](mailto:shinnm@mail.nih.gov).

This technology is a fluorescent protein for discrete tracing of intra- and intercellular connections and for sorting and isolation of cells. This recombinantly engineered protein can be expressed from viral vectors for use in living animals and in *ex vivo* situations involving primary cultured

cells or from a plasmid for use in cell lines. The new protein consists of a fusion between the tau protein, which binds to microtubules, and enhanced green fluorescent protein (tau-eGFP). When cloned into adenovirus, the contrast can be used for transducing primary cultures for *ex vivo* gene therapy and for use as an anterograde tracer in brain circuit analysis. These uses can be a valuable research tool to help scientists find out how the brain works, investigate Alzheimer's disease, and to identify specific cells for treating disease via cell transplantation.

Dated: July 19, 2005.

#### **Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 05-15348 Filed 8-2-05; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Cancer Institute; Notice of Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the President's Cancer Panel.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), title 5 U.S.C., as amended, because the premature disclosure of information and the discussions would likely to significantly frustrate implementation of recommendations.

*Name of Committee:* President's Cancer Panel.

*Date:* August 25, 2005.

*Open:* August 25, 2005, 8 a.m. to 2:30 p.m.  
*Agenda:* Cancer Survivorship: Treatment Records, Follow-up, and HIPPA.

*Place:* The Washington Marriott Hotel, 1221 22nd Street, NW., Washington, DC 20037.

*Closed:* August 25, 2005, 3 p.m. to 5 p.m.  
*Agenda:* The Panel will discuss the treatment records and follow-up care plans.

*Place:* The Washington Marriott Hotel, 1221 22nd Street, NW., Washington, DC 20037.

*Contact Person:* Abby Sandler, Ph.D., Executive Secretary, National Cancer

Institute, National Institutes of Health, Building 6116, Room 212, 6116 Executive Boulevard, Bethesda, MD 20892. (301) 451-9399.

Any interested person may file written comments with the committee by forwarding the comments to the Contact Person listed on this notice. The comments should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's Home page: <http://deainfo.nci.nih.gov/advisory/pcp/pcp.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS).

Dated: July 26, 2005.

#### **Anthony M. Coelho, Jr.,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-15243 Filed 8-2-04; 8:45 am]

**BILLING CODE 4140-01-M**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Heart, Lung, and Blood Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel, Genetics of Alaska Natives.

*Date:* August 16, 2005.

*Time:* 9 a.m. to 11 a.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Room 7214, Bethesda, MD 20892. (Telephone conference call.)

*Contact Person:* Valerie L. Prenger, PhD, Health Scientist Administrator, Review Branch, Room 7214, Division of Extramural Affairs, National Heart, Lung, and Blood Institutes, 6701 Rockledge Drive, MSC 7924, Bethesda, MD 20892-7924. (301) 435-0270. [prengerv@nhlbi.nih.gov](mailto:prengerv@nhlbi.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS.)

Dated: July 27, 2005.

**Anthony M. Coelho, Jr.,**

*Deputy Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-15244 Filed 8-2-05; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Human Genome Research Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Human Genome Research Institute Special Emphasis Panel Screening Assay Development for SCD.

*Date:* August 12, 2005.

*Time:* 11 a.m. to 2 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 5635 Fishers Lane, Rockville, MD 20852. (Telephone conference call.)

*Contact Person:* Ken D. Nakamura, PhD, Scientific Review Administrator.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS)

Dated: July 26, 2005.

**Anthony M. Coelho, Jr.,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-15240 Filed 8-2-05; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The contract and proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel, ZAA1 CC (48)—SBIR Contract Application.

*Date:* August 10, 2005.

*Time:* 2 p.m. to 4 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, 1070, Bethesda, MD 20892. (Telephone conference call.)

*Contact Person:* Mahadev Murthy, PhD, MBA, Scientific Review Administrator, Extramural Project Review Branch, Office of Extramural Activities, National Institute on Alcohol Abuse and Alcoholism, MSC 9304, Room 3037, Bethesda, MD 20892-9304. (301) 443-0800. [mmurthy@nih.gov](mailto:mmurthy@nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel, ZAA1 CC (49)—SBIR Contract Application.

*Date:* August 12, 2005.

*Time:* 10:30 a.m. to 12:30 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, 1070, Bethesda, MD 20892. (Telephone conference call.)

*Contact Person:* Mahadev Murthy, PhD, MBA, Scientific Review Administrator, Extramural Project Review Branch, Office of

Extramural Activities, National Institute on Alcohol Abuse and Alcoholism, MSC 9304, Room 3037, Bethesda, MD 20892-9304. (301) 443-0800. [mmurthy@nih.gov](mailto:mmurthy@nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol Research Center Grants, National Institutes of Health, HHS.)

Dated: July 26, 2005.

**Anthony M. Coelho, Jr.,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-15241 Filed 8-2-05; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Nursing Research; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council for Nursing Research.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552(b)(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council for Nursing Research.

*Date:* September 13-14, 2005.

*Open:* September 13, 2005, 1 p.m. to 5 p.m.

*Agenda:* Discussion of Program Policies and Issues.

*Place:* National Institutes of Health, Building 31, Room 10, 31 Center Drive, Bethesda, MD 20892.

*Closed:* September 14, 2005, 9 a.m. to 2 p.m.

*Agenda:* To review and evaluate grant applications.